FDA Brief

Warning letters Drugs

FDA warning letter to

ImprimisRx NJ

Issued May 26, 2023Posted Jun 6, 2023Division of Pharmaceutical Quality Operations I

Compounding Pharmacy/Adulterated Drug Products. We haven't summarized this letter yet. Read it on fda.gov.

ImprimisRx NJ's FDA history

Recalls in the last 12 months

Sep 16 Class III ImprimisRx NJ LLC
Drug
Povidone Iodine 1.25% / Proparacaine HCl 0.5% Ophthalmic Solution, 10 mL per dropper bottle, For Office Use Only, Imprimis NJOF, LLC, 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852, NDC 71384-732-10
Subpotent Drug

Full company page